GABRG2 Gene Genetic Test (Childhood Absence Epilepsy Type 2) in UAE | 2800 AED | 2026 DHA Guidelines

The GABRG2 Genetic Test provides definitive molecular diagnosis of Childhood Absence Epilepsy Type 2 by sequencing the entire coding region of the GABRG2 gene with high-depth coverage. This test is indicated for children and adolescents presenting with typical absence seizures (brief staring spells with impaired consciousness), especially when there is a family history of epilepsy, when EEG findings are suggestive of generalized spike-wave discharges, or when a precise genetic diagnosis is needed to guide antiepileptic drug selection and prognostic counselling.

A certified phlebotomist collects a standard 3–5 mL EDTA whole blood sample via venipuncture during our home collection service available daily from 8 AM to 11 PM. The sample is transported under ISO-certified cold-chain conditions to our DHA-licensed laboratory, where NGS sequencing and bioinformatic analysis are performed over a period of 3 to 4 weeks. A comprehensive clinical report is then issued, and a telephonic post-test counselling session is scheduled to discuss the results with you and your treating neurologist.

A positive (pathogenic) GABRG2 result confirms the genetic etiology of childhood absence epilepsy type 2, which can inform antiepileptic drug selection — for instance, guiding clinicians toward medications that enhance GABAergic transmission while avoiding those that may exacerbate absence seizures. A negative result does not rule out epilepsy but shifts diagnostic focus to other genes or acquired etiologies. For family planning, identification of a pathogenic variant enables cascade testing of at-risk relatives and informs recurrence risk counselling for future pregnancies, with autosomal dominant inheritance carrying a 50% transmission probability per pregnancy.